Vascular normalization due to VEGF-inhibiting therapy exhibited increased lymphocyte infiltration and T-cell activation which, combined with immune checkpoint inhibitors (ICI), elicited an improved anti-tumor immunity in preclinical trials (Allen et al., 2017; Schmittnaegel et al., 2017). Here, VEGFA is linked to neoplasm.